Mitapivat, a novel experimental agent, represents a promising advancement in the treatment of erythroid disorders such as pyruvate kinase deficiency (PKD). This unique compound functions as a potent PKR, boosting its activity and, consequently, enhancing erythropoiesis. Its function is believed to ameliorate metabolic abnormalities seen in these… Read More